#80: Defeating Dementia - Installment #8
Email This Show To A Colleague
Installment #8 of Defeating Dementia - Promising news and approaches for progressive brain disorders.
Treat Alzheimer’s Early With Cholinesterase Inhibitors, Treat Long Term?
- At 1 year, patients on donepezil were significantly less likely to convert to Alzheimer’s disease. Over a year and a half, they did better on thinking, memory, and daily functioning measures, but by 3 years, there was no difference in the rate of conversion to Alzheimer?s signs and symptoms.
- Listeners are reminded of the potential importance of the likely neuroborreliosis etiology of Alzheimer’s; also the free CSF testing for evidence of the bug, being offered by Dr. Alan MacDonald in his research. Contact Dr. MacDonald via his website www.molecularalzheimer.org
- We also reflect briefly on research focusing on the use of vitamin E to reduce Alzheimers. The National Guideline Clearinghouse says vitamin E should be considered - at 1000 I.U. PO BID - in an attempt to slow progression of Alzheimer’s disease. Not a cure, but maybe Alzheimer’s patients can live longer and have better health if they take vitamin E.
Rivastigmine Patch Gets Approval for Dementia: It?s the second patch approved for Parkinson’s disease. One of the researchers (a consultant for the manufacturer, Novartis) said the patch appears better tolerated than the pill.
Alzheimer’s Disease Affects 5 Million: The prevalence is projected to skyrocket in the next 40 years.
Money and Leadership Sought As Alzheimer’s Crisis Looms: The Center for Health Transformation is a health policy think tank founded by former Speaker of the House Newt Gingrich. The Center has a national financial-plus-leadership strategic plan intended to tackle the impending Alzheimer’s epidemic.
Race and Ethnicity Play Role in Alzheimer’s Treatment Delays: The survey found that essentially 70% of both African American and Hispanic caregivers were likely to dismiss the symptoms of Alzheimer’s as “old age” compared with just 50% of caregivers of other races. And African American caregivers were more likely to report that stigma of the diagnosis affected their decision to obtain a diagnosis for a family member.
CAIDE Dementia Risk Score Validated: This risk score predicts the likelihood of a middle-aged person developing dementia within 20 years. It has been independently validated in an ethnically diverse population.
Imaging Compound Pittsburgh B May Help Track Alzheimer’s: The investigational Pittsburgh B compound that binds to cerebral -amyloid and is visible on positron emission tomography — PET scans — maintains its promise as a way to distinguish the elderly patients presenting with memory problems who will go on to develop Alzheimer’s disease from those who won’t progress.
Stroke in Early Alzheimer’s Ups Dementia Risk: The interaction of cerebrovascular disease and Alzheimer’s disease pathology appears to significantly increase the risk of dementia from Alzheimer’s, even when only a small amount of Alzheimer’s pathology is present.
And Last but not least: Marijuana’s active ingredient, THC, acts as a cholinesterase inhibitor and may slow the progression of Alzheimer’s disease.
Next week’s show: Our 5th installment of Vulnerability in Neurology - Potential challenges for neurologists on the clinical front lines. Tune in as we discuss insights about the doctor shortage from the results of a large survey done on hospital CEOs. We’ll have other important vulnerability-related news too.
Weblink (other): Alzheimer’s is the 3rd most expensive medical condition in the US. The direct and indirect costs of Alzheimer’s disease add up to essentially $150 billion each year. That?s on the ?billions scale? the Iraq war is costing us each year. BTW: Click here for an interesting website showing a running total estimate of the ongoing costs of the Iraq war.
To provide us with your feedback:
E-mail: feedback@MedicalNewsPodcasts.com;
Call our comment line: 206-202-1043; or Leave Comments (0)
